U.S. market projected to grow from USD 27.27 billion in 2025 to USD 138.15 billion by 2035 at a 17.61% CAGR, while Europe is expected to rise from USD 16.84 billion to USD 78.24 billion over the same ...
Glucagon-like peptide-1 (GLP-1) was first discovered in the 1980s as a regulator of glucose levels. Further research led to the creation of a stabilized GLP-1RA called semaglutide, the active ...
Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella ...
Drugs like Ozempic, Wegovy and Mounjaro have been around for years, but they've recently been making headlines due to a rise in popularity as weight loss agents. They all belong to a class of drugs ...
SHANGHAI, China & XIAMEN, China & ALBANY, N.Y.--(BUSINESS WIRE)--Drug Farm, a private biotechnology company utilizing genetics and artificial intelligence technologies to discover and develop ...
The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation involving this class of drugs. Over the past few years, ...
GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
The Annals of Pharmacotherapy. 2012;46(5):710-717. There are several limitations to the available data. First, single-dose drug interaction studies do not permit examination of the effects of repeat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results